On March 27, 2023 Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC) technology to address gaps in cancer care, reported the upcoming poster presentation of new preclinical data for ACE2016, a gamma delta-2 T cell therapy designed to target EGFR expressing solid tumors (Press release, Acepodia, MAR 27, 2023, View Source [SID1234629395]). The company will present this data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting in Orlando, Florida, April 14-19, 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation will showcase data demonstrating the in vitro and in vivo efficacy of ACE2016 against EGFR-expressing cancer cells which warrant investigation of potential clinical application in EGFR-expressing tumors.
Details on the presentation and session are provided below:
Presentation details
Presentation Title: ACE2016: an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors
Session Title: Late-Breaking Research: Immunology 1
Session Date and Time: Monday Apr 17, 2023 9:00 AM – 12:30 PM
Location: Poster Section 35
Poster Board Number: 5
Abstract Presentation Number: LB089
"The poster presentation at this year’s AACR (Free AACR Whitepaper) is an exciting opportunity for Acepodia to showcase preclinical data for ACE2016 as a potential off-the-shelf cell therapy which exploits the ability of gamma delta T cells to recognize and engage solid tumors expressing EGFR by ACC technology unlocking multiple receptor signaling," said Sonny Hsiao, Ph.D., chief executive officer and co-founder of Acepodia. "We look forward to presenting the preclinical data in more details in the poster session at AACR (Free AACR Whitepaper), and to further evaluating this exciting modality for solid tumor patients."
About Gamma-Delta T Cells
Acepodia’s gamma delta T cell program harnesses the unique properties of gamma delta T cells to develop a new class of off-the-shelf cell therapies for the treatment of cancer. Gamma delta T cells have characteristics of both the innate and adaptive immune systems that make them an ideal chassis for the development of cell therapies. This cell type can recognize and attack cancerous cells as well as coordinate a broad antitumor immune response by recruiting other immune factors and cells to the site of disease. Gamma delta T cells have also been shown to preferentially traffic to distinct tissues and could be ideally suited for more targeted treatment of certain types of cancers.